Search criteria | ||||
Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions | ||||
Oriol Sola- Morales (1), Lesley H. Curtis (2), Julien Heidt (3),*, Laura Walsh (4), Deborah Casso (5),?, Susan Oliveria (6),?, Patrick Saunders- Hastings (7), Yufei Song (8),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9) | ||||
(1) Fundació Health Innovation Technology Transfer and International, University of Catalonia, Barcelona, Spain; (2) Duke Clinical Research Institute, Durham, North Carolina, USA; (3) IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; (4) IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; (5) IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; (6) IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; (7) Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; (8) IQVIA, Epidemiology and Drug Safety Practice, Beijing, China; (9) Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA | ||||
Clinical pharmacology and therapeutics vol. 114,2 (2023): 325-355. doi:10.1002/cpt.2914 |
||||
, Article | ||||
, Europe, USA | ||||
Abstract: https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2914 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory | 2023 | English | , Review | |
High‑Expenditure Disease in the EU‑28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? | ||||
Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck | ||||
Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium | ||||
PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4 |
||||
, Article | ||||
, Europe | ||||
Abstract: https://link.springer.com/epdf/10.1007/s41669-020-00253-4?sharing_token=k4IP2sUMn4HrAsHs0WBqlPe4RwlQNchNByi7wbcMAY4Tirkz8MqaNXdxznG7LjXgeeOE1lL_TUFtfOXdhNB_IQ05wAS6SyWtTgC3QV4GkZ1V3rKbHAI_lwyKV2fZ5OfrjVrTPTsYaJr4E7ZctQaMI_Yhmg_dNtoFcG1705dWSU4%3D | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics, Oncology | 2021 | English | , Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review | |
How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools | ||||
Elvira D'Andrea, Lydia Vinals, Elisabetta Patorno, Jessica M. Franklin, Dimitri Bennett , Joan A. Largent, Daniela C. Moga, Hongbo Yuan, Xuerong Wen, Andrew R. Zullo, Thomas P. A. Debray, Grammati Sarri | ||||
D'Andrea: Harvard; Largent: IQVIA | ||||
http://orcid.org/0000-0002-5263-3964PubMed articles |
||||
, Article | ||||
, Europe, USA | ||||
Abstract: https://bmjopen.bmj.com/content/11/3/e043961 | ||||
Condition | Year | Language | Analysis type | |
, Methodology | 2021 | English | , Literature Review | |
Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making | ||||
Grammati Sarri 1, Elisabetta Patorno 2, Hongbo Yuan 3, Jianfei Jeff Guo 4, Dimitri Bennett 5, Xuerong Wen 6, Andrew R Zullo 7, Joan Largent 8, Mary Panaccio 9, Mugdha Gokhale 10, Daniela Claudia Moga 11, M Sanni Ali 12 13 14, Thomas P A Debray 15 16 | ||||
1Real World Evidence Sciences, Visible Analytics Ltd, Oxford, UK grammati.sarri@visibleanalytics.co.uk. 2Division of Pharmacoepidemiology and Pharmacoeconomics, Dept. of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, Ontario, Canada. 4Department of Pharmacy Practice & Administrative Sciences, University of Cincinnati College of Pharmacy, Cincinnati, Ohio, USA. 5Takeda, Cambridge, Massachusetts, USA. 6Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA. 7Health Services, Policy, and Practice, Brown University, Providence, Rhode Island, USA. 8Real-World Solutions, IQVIA, California, Colorado, USA. 9Epidemiology and Outcomes Research, Research Outcomes Innovations LLC, New York City, New York, USA. 10GlaxoSmithKline USA, Philadelphia, Pennsylvania, USA. 11University of Kentucky, Department of Pharmacy Practice and Science, Lexington, Kentucky, USA. 12NDORMS, Center for Statistics in Medicine, University of Oxford, Oxford, UK. 13Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine (LSHTM), London, UK. 14Department of Public Heath, Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine (LSHTM), London, UK. 15Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands. 16Smart Data Analysis and Statistics, Utrecht, The Netherlands. | ||||
PMID: 33298465 DOI: 10.1136/bmjebm-2020-111493 |
||||
, Article | ||||
, Europe, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33298465/ | ||||
Condition | Year | Language | Analysis type | |
, Methodology | 2021 | English | , Literature Review | |
Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE | ||||
P. Escribano (1), S. Gaine (2), P. Biedermann (3), A. Muller (3), M. Valge (4), T. Lange (5), S. Söderberg (6) | ||||
1 Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 de Octubre, Madrid, Spain 2 National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland 3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland 4 StatFinn Estonia OÜ, Tartu, Estonia (now IQVIA) 5 University Medical Center Regensburg, Regensburg, Germany 6 Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, Sweden | ||||
JO - The Journal of Heart and Lung Transplantation VL - 40 IS - 4, Supplement SP - S109 PY - 2021 DA - 2021/04/01/ SN - 1053-2498 |
||||
, Abstract | ||||
, Canada, Europe | ||||
Abstract: https://www.jhltonline.org/article/S1053-2498(21)00365-X/fulltext#articleInformation | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2021 | English | , Epidemiological study, Observational study | |
A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe. | ||||
Jouaville LS, Paul T, Almas MF | ||||
IQVIA | ||||
Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1143-1152. doi: 10.1002/pds.5301. |
||||
, Article | ||||
, Europe | ||||
Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5301 | ||||
Condition | Year | Language | Analysis type | |
, Guidelines, Methodology, Risk Management & REMS | 2021 | English | , Literature Review | |
Interventional or Non-Interventional? Analyzing the Differences Between Clinical Studies Using Medicines in the European Union | ||||
Tiago Silva, MSc; Alexandra Parnell, MSc; Christopher Bamford, PhD; Catherine Paulen, PharmD; Simona Francisconi, MSc; Jaclyn Bosco, PhD, MPH; Louise Parmenter, PhD, MSc | ||||
Clinical Researcher February 2020; Volume 34, Issue 2 |
||||
, Article, Online article | ||||
, Europe | ||||
Abstract: https://acrpnet.org/2020/02/11/interventional-or-non-interventional-analyzing-the-differences-between-clinical-studies-using-medicines-in-the-european-union/ | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice | 2020 | English | , Population Based Study, Retrospective database analysis | |
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study | ||||
Gerard E.Franciscoa; Daniel S.Bandari; Ganesh Bavikattec; Wolfgang H.Jost; Emily McCusker; Joan Largent; Alekse Zuzek; Alberto Esquenazi | ||||
a The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA b Multiple Sclerosis Center of California & Research Group, Newport Beach, CA, USA c The Walton Centre, Liverpool, UK d University of Freiburg, Department of Neurology, Freiburg im Breisgau, Germany e Parkinson-Klinik Ortenau, Wolfach, Germany f Allergan, an AbbVie Company, Irvine, CA, USA g IQVIA Real-World Evidence Solutions, Cambridge, MA, USA h MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA | ||||
PM R . 2020 Jan 17. doi: 10.1002/pmrj.12328. PMID: 31953896 DOI: 10.1002/pmrj.12328 |
||||
, Article | ||||
, Asia Pacific, Europe, USA | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S2590171020300187?via%3Dihub | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Medication compliance | 2020 | English | , Methodology, Observational study | |
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study | ||||
Gerard E Francisco 1, Daniel S Bandari 2, Ganesh Bavikatte 3, Wolfgang H Jost 4 5, Emily McCusker 6, Joan Largent 7, Aleksej Zuzek 6, Alberto Esquenazi 8 | ||||
1The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA. 2Multiple Sclerosis Center of California & Research Group, Newport Beach, CA, USA. 3The Walton Centre, Liverpool, UK. 4University of Freiburg, Department of Neurology, Freiburg im Breisgau, Germany. 5Parkinson-Klinik Ortenau, Wolfach, Germany. 6Allergan, an AbbVie Company, Irvine, CA, USA. 7IQVIA Real-World Evidence Solutions, Cambridge, MA, USA. 8MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA. | ||||
PMID: 32875289 PMCID: PMC7452133 DOI: 10.1016/j.toxcx.2020.100040 |
||||
, Article | ||||
, Europe, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/32875289/ | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2020 | English | , Epidemiological study, Observational study | |
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study | ||||
Gerard E Francisco 1, Wolfgang H Jost 2, Ganesh Bavikatte 3, Daniel S Bandari 4, Simon F T Tang 5, Michael C Munin 6, Joan Largent 7, Aubrey M Adams 8, Aleksej Zuzek 8, Alberto Esquenazi 9 | ||||
1The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX. 2Department of Neurology, University of Freiburg, Freiburg im Breisgau, Germany. 3The Walton Centre, Liverpool, UK. 4Multiple Sclerosis Center of California & Research Group, Newport Beach, CA. 5Department of Physical Medicine and Rehabilitation, Lotung Poh-Ai Hospital, Yilan, Taiwan. 6Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, PA. 7IQVIA Real-World Evidence Solutions, Cambridge, MA. 8Allergan plc, Irvine, CA. 9MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA. | ||||
PMID: 31953896 PMCID: PMC7687094 DOI: 10.1002/pmrj.12328 |
||||
, Article | ||||
, Asia Pacific, Europe, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/31953896/ | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2020 | English | , Epidemiological study, Observational study | |
Outcome measurement in pregnancy exposure registries: A preliminary review of publicly available resources | ||||
Suzanne N. Landi, Jessica R. Probst , Katherine Lee, , Elsa GarcÃa Hernández , Kristen Hahn | ||||
IQVIA, Durham, NC NoviSci Inc., Durham, NC | ||||
, Europe, USA | ||||
Condition | Year | Language | Analysis type | |
, Pregnancy | 2019 | English | , Population Based Study, Review | |
Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Pregnancy study conducted in Finland and Sweden | ||||
"Kerstin Hellwig*, Yvonne Geissbuehler2, Meritxell Sabidó3, Catrinel Popescu4, Alessandra Adamo5, Joachim Klinger6, Peter Huppke7, Asher Ornoy8, Pasi Korhonen9, Kjell-Morten Myhr10, Scott Montgomery11, Sarah Burkill11, European Interferon Beta Pregnancy Study Group" | ||||
*Katholisches Klinikum Bochum, St Josef-Hospital Universitatsklinikum, Bochum, Germany; 9StatFinn & EPID Research, Espoo, Finland | ||||
AAN, Philadelphia, USA, 4-10 May 2019 |
||||
, Oral presentation | ||||
, Europe, Finland, Nordic, Sweden | ||||
Abstract: https://n.neurology.org/content/92/15_Supplement/S49.005 | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2019 | English | , Epidemiological study, Population Based Study | |
Patterns of Therapy in Regional Lymph Node Positive Prostate Cancer in Europe and Asia: An International Analysis | ||||
Prentice M1, Mpima S2, Martinez S2, Nasuti P2, Davda R1, Payne H1 | ||||
1 University College Hospital, London, UK, 2 IQVIA , London, UK | ||||
, Asia Pacific, Europe | ||||
Condition | Year | Language | Analysis type | |
2018 | English | |||
Profiling and treatment patterns in NSCLC patients with CNS (brain) metastases in Europe and Asia | ||||
Mari E1, Mpima S2, Guglielmetti F1, Nasuti P2, Manuguid F2, Heitner Enschede S3 | ||||
1IQVIA , Milan, Italy 2IQVIA , London, UK 3IQVIA Inc, USA | ||||
JCO ( ASCO 2018) |
||||
, Abstract | ||||
, Asia Pacific, China, Europe, France, Germany, Italy, Japan, South Korea, Spain, UK | ||||
Abstract: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e21085 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
EVALUATING NSCLC TREATMENT OPTIONS USING REAL WORLD DATA: FINDINGS FROM AN ONCOLOGY SURVEY ACROSS EIGHT COUNTRIES | ||||
Takeno S1, Tanaka S1, Saijo N1 Nasuti P2 | ||||
1IQVIA Solutions Japan K.K., Tokyo, Japan, 2IQVIA , London, UK | ||||
ISPOR 2018 APAC |
||||
, Poster | ||||
, Asia Pacific, Europe | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Neue Krebstherapeutika: Personalisierte Medizin eröffnet neuartige Therapieoptionen | ||||
Hoyer L , Schmidt L | ||||
IQVIA Frankfurt Germany | ||||
Pharmamind |
||||
, Article | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | German | ||
Evaluating Renal Cell Carcinoma treatment options using real world data: findings from an oncology survey across seven countries | ||||
S. Mpima, S. Menon, P. Nasuti, H. Mistry | ||||
IQVIA London UK | ||||
ESMO - ImmunoOncology |
||||
, Poster | ||||
, Asia Pacific, Europe | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2017 | English | ||
Real World analysis for immune related side effects in 3000 patients | ||||
Mitrofan L 1, Moehler T 2, Ruiz M 3 | ||||
1IQVIA Paris , France 2IQVIA , Frankfurt, Germany, 3IQVIA, Madrid, Spain | ||||
ESMO - ImmunoOncology |
||||
, Poster | ||||
, Europe, France, Germany, Spain, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2017 | English | ||
Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics | ||||
Gerard E Francisco 1, Daniel S Bandari, Ganesh Bavikatte, Wolfgang H Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi | ||||
Francisco: The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann; Largent: IQVIA | ||||
PMID: 28805237 DOI: 10.2340/16501977-2245 |
||||
, Article | ||||
, Asia Pacific, Europe, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/28805237/ | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2017 | English | , Epidemiological study, Observational study | |
Effectiveness of a Risk-Minimization Activity Involving Physician Education on Metabolic Monitoring of Patients Receiving Quetiapine: Results from Two Post-Authorization Safety Studies | ||||
Robert S. Brody, Charles L. Liss, Heather Wray, Ramon Iovin, Carmen Michaylira, Anushini Muthutantri, Philip Damstetter, Catherine Datto, Leigh Jefferies | ||||
Int Clin Psychopharmacol. 2016 Jan;31(1):34-41. |
||||
, Article | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2016 | English | , Survey research | |
Direct and indirect protection with paediatric influenza vaccination in Europe estimated by a dynamic transmission model. | ||||
Gerlier L, Hackett J, Lawson R, Weil-Olivier C, Schwehm M, Eichner M. | ||||
Options IX for the control of Influenza, 2016, August 24-28, Chicago, IL, USA |
||||
, Podium presentation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease | 2016 | English | ||
Real-world treatment with abiraterone acetate (Zytiga®) in metastatic castration-resistant prostate cancer (mCRPC) patients in the post-chemotherapy setting in Europe | ||||
L Dearden, P Musingarimi, N Shalet, T Maher, D Demuth, L Garcia-Alvarez, A Muthutantri, A Venerus, R Lasry, M Hankins | ||||
, Conference | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Methodology, Oncology | 2015 | English | , Real World Data, Real World Evidence | |
Parents’ expressed emotion and mood, rather than their physical disability are associated with adolescent adjustment: A longitudinal study of families with a parent with multiple sclerosis | ||||
A Bogosian 1, J Hadwin 2, M Hankins 3, R Moss-Morris 4 | ||||
1 Psychology Department, City University, UK 2 Psychology Department, Southampton University, UK 3 Real-World Evidence Solutions, IMS Health, UK 4 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, | ||||
Clin Rehabil. 2015 Apr 14 |
||||
, Article | ||||
, England, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25872520 | ||||
Condition | Year | Language | Analysis type | |
, Musculoskeletal disease, Neurological disorders, Oncology | 2015 | English | , Longitudinal study | |
Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. | ||||
Pacurariu AC1,2, Straus SM1,2, Trifirò G1,3, Schuemie MJ1, Gini R4, Herings R5, Mazzaglia G6, Picelli G7, Scotti L8, Pedersen L9, Arlett P10, van der Lei J1, Sturkenboom MC1, Coloma PM11. | ||||
1Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.2Dutch Medicines Evaluation Board, Utrecht, The Netherlands. • 3Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.4Agenzia Regionale di Sanità della Toscana, Florence, Italy.5PHARMO Institute, Utrecht, The Netherlands.6Società Italiana di Medicina Generale, Florence, Italy.7Pedianet-Società Servizi Telematici SRL, Padua, Italy. • 8Department of Statistics, Università di Milano-Bicocca, Milan, Italy.9Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.10European Medicines Agency, London, UK.11Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands | ||||
Drug Saf. 2015 Sep 14 |
||||
, Abstract, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26370104 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety | 2015 | English | , Retrospective database analysis, Survey research | |
Comparative Effectiveness Research (CER) of Treatments for Advanced Melanoma in Europe Using Existing Real-World Data Sources: A Feasibility Assessment | ||||
Daumont MM, Juuti R, Hoeller C, Zagorska A, Mertano E, Korhonen P | ||||
Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France | ||||
Pigment Cell & Melanoma Research (2015) 28 (6), pp. 753-826 |
||||
, Abstract | ||||
, Europe | ||||
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.12419 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Oncology | 2015 | English | , Literature Review, Review | |
ENCePP-HTA Working Group 2014 survey of members experience in conducting research to support HTA | ||||
Blake K1, Toussi M2, Kurz X1, Lis Y3, Ehrenstein V4, Qizilbash N5, Moore N6 | ||||
1 for the ENCePP-HTA Working Group, European Medicines Agency, London, UK 2 IMS Health, Paris, France 3 Parexel, London, UK 4 Aarhus University Hospital, Aarhus, Denmark 5 Oxon Epidemiology Ltd, London, UK 6 University of Bordeaux, Bordeaux, France | ||||
17th European Congress of ISPOR |
||||
, Abstract | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Methodology | 2014 | English | , Survey research, Workshop | |
Future access to innovative oncology drugs in the EU: Evolution and proactive application of real-world evidence | ||||
McDonell A1, Opel M1, Berger K2 | ||||
1 IMS Health, London, UK 2 IMS Health, Munich, Germany | ||||
AccessPoint, 2014, May; 4(8): 32-35 |
||||
, Article | ||||
, Europe | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Oncology | 2014 | English | , Real World Evidence | |
C-reactive protein levels in patients at cardiovascular risk: EURIKA study. | ||||
Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, Guallar E, Sazova O, Medina J, Perk J, Steg PG, RodrÃguez-Artalejo F, Borghi C. | ||||
BMC Cardiovascular Disorders 2014, 14:25 doi:10.1186/1471-2261-14-25 |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.biomedcentral.com/1471-2261/14/25 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Prospective study | |
HERPES ZOSTER-RELATED HEALTHCARE RESOURCE USE IN CANCER PATIENTS IN FIVE EUROPEAN COUNTRIES | ||||
Berhanu Gebremeskel, MD, MPH, MSCE(c.)1a, Lorena Lopez-Gonzalez, PhD2 ,Pallavi Patwardhan, PhD, BSPharm1b, Jiyoung Chin, PhD3,Marie-Sophie Schwalm, MS4, Camilo Acosta, MD, PhD1a, Jay Margolis, PharmD5 | ||||
1Merck & Co. Inc., (aWest Point, PA, bCokesbury, NJ) Whitehouse Station, NJ, USA;2Truven Health Analytics, Austen, TX, USA; 3Cegedim Strategic Data, Jersey City, NJ, USA; 4Cegedim Strategic Data, Paris, France; 5Truven Health Analytics, Bethesda, MD, USA | ||||
ISPOR 17th Annual European Congress 8-12 November 2014 Amsterdam RAI Amsterdam, The Netherlands |
||||
, Poster | ||||
, Europe | ||||
Abstract: http://www.ispor.org/event/ProgramList/2014Amsterdam?type=Poster&sess=V&acode=PIN | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease, Oncology | 2014 | English | , Retrospective database analysis | |
Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. | ||||
Valkhoff VE1, Coloma PM2, Masclee GM1, Gini R3, Innocenti F4, Lapi F5, Molokhia M6, Mosseveld M2, Nielsson MS7, Schuemie M2, Thiessard F8, van der Lei J2, Sturkenboom MC9, Trifirò G10; EU-ADR Consortium. | ||||
1Department of Medical Informatics, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam The Netherlands.2Department of Medical Informatics, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.3Agenzi Regionali di Sanità della Toscana, Via Pietro Dazzi 1 - 50141, Firenze, Italy.4Health Search, Italian College of General Practitioners, Via del Pignoncino, 9-11,50142, Florence, Italy.5Centre for Clinical Epidemiology, Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montréal, QC H3T 1E2, Canada; Department of Preclinical and Clinical Pharmacology, University of Florence, Piazza di San Marco, 4, 50121 Firenze, Italy.6Department of Primary Care and Public Health Sciences, Kings College London, Division of Health and Social Care Research, 7th Floor, Capital House, 42 Weston Street, London SE1 3QD, United Kingdom.7Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45 DK-8200 Aarhus N, Denmark.8LESIM, ISPED, Universite Bordeaux 2', 146 Rue Léo Saignat, 33076 Bordeaux, France.9Department of Medical Informatics, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands; Department of Epidemiology, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.10Department of Medical Informatics, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands; Department of Clinical and Experimental Medicine and Pharmacology, Via Consolare Pompea, 1, Messina, University of Messina, Italy. | ||||
J Clin Epidemiol. 2014 Aug;67(8):921-31. doi: 10.1016/j.jclinepi.2014.02.020. Epub 2014 May 1. |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24794575 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Gastrointestinal disorders | 2014 | English | , Retrospective database analysis | |
Review of cost of diabetes complications in four European countries | ||||
Beaudet A1, Grabbi E2, Maurel F3, Ramos M4, Lebioda A2 | ||||
1 IMS Health, Basel, Switzerland, 2 IMS Health, London, UK, 3 IMS Health, Paris, France, 4 IMS Health, Barcelona, Spain | ||||
ISPOR 16th annual European congress, 2013, November 2-6, Dublin, Ireland |
||||
, Poster | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2013 | English | , Cost of illness, Review | |
Identification and qualitative assessment of real world data sources: example of lymphoma and multiple myeloma in Europe | ||||
Noibi S1, Bertwistle D1, MacDougall F1, Berger K2, Mehta J3, Trask P3 | ||||
1IMS Health, London, UK, 2IMS Health, Munich, Germany, 3Sanofi, Cambridge, MA, USA | ||||
ISPOR 16th Annual European Congress, 2013. PRM48. |
||||
, Abstract, Poster | ||||
, Europe | ||||
Abstract: http://www.ispor.org/Events/Posters.aspx?eventId=42&sess=V | ||||
Condition | Year | Language | Analysis type | |
, Hematology, Oncology | 2013 | English | , Real World Data | |
Understanding patterns of monitoring of appropriate prescribing in Europe | ||||
Schroeder C1, Keja J2, Toussi M3, Hughes B2 | ||||
1 IMS Health, Munich, Germany 2 IMS Health, London, UK 3 IMS Health, Paris, France | ||||
ISPOR 16th annual european congress, 2013, November 2-6, Dublin, Ireland |
||||
, Poster | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Regulatory | 2013 | English | , Review | |
Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. | ||||
Banegas JR1, López-GarcÃa E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Massó-González EL, Sazova O, Perk J, Steg PG, De Backer G, RodrÃguez-Artalejo F. | ||||
1Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ, CIBER of Epidemiology and Public Health, Madrid, Spain | ||||
Int J Cardiol. 2013 Jun 5;166(1):210-4. doi: 10.1016/j.ijcard.2011.10.094. Epub 2011 Nov 5 |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22056474 | ||||
Condition | Year | Language | Analysis type | |
, Metabolic Disorders | 2013 | English | , Prospective study | |
An inventory of European data sources for the long-term safety evaluation of methylphenidate. | ||||
Murray ML, Insuk S, Banaschewski T, Neubert AC, McCarthy S, Buitelaar JK, Coghill D, Dittmann RW, Konrad K, Panei P, Rosenthal E, Sonuga-Barke EJ & Wong IC. | ||||
Centre for Paediatric Pharmacy Research, University College London School of Pharmacy, London, UK | ||||
Eur Child Adolesc Psychiatry. 2013 Oct;22(10):605-18. doi: 10.1007/s00787-013-0386-x. Epub 2013 Mar 19. |
||||
, Article | ||||
, Europe, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23508655 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Mental health, Pediatrics | 2013 | English | , Database Study, Methodology, Retrospective database analysis | |
Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? | ||||
Gwen MC Masclee1,2, Vera E Valkhoff1,2, Eva M van Soest1, René Schade1,Giampiero Mazzaglia3, Mariam Molokhia4, Gianluca Trifirò1,5, Jay L Goldstein6, Sonia HernándezDÃaz7,Ernst J Kuipers2,8, and Miriam C J M Sturkenboom1,9 | ||||
1Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands. 2Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 3Health Search, Italian College of General Practitioners,Florence, Italy. 4Primary Care & Public Health Sciences, Kings College London, London, United Kingdom. 5Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy. 6Department of Medicine, Division of Gastroenterology, NorthShore University HealthSystem, Evanston, Illinois, USA. 7Department of Epidemiology, Harvard School of Public Health, Boston, USA. 8Department of Internal Medicine, Erasmus University Medical Centre,Rotterdam, The Netherlands. 9Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, The Netherlands. | ||||
Aliment Pharmacol Ther. 2013 Jul;38(2):178-89 |
||||
, Article | ||||
, Europe, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23710837 | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2013 | English | , Retrospective database analysis | |
Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. | ||||
Avillach P1, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour JC, Mazzaglia G, Giaquinto C, Fornari C, Herings R, Molokhia M, Pedersen L, Fourrier-Réglat A, Fieschi M, Sturkenboom M, van der Lei J, Pariente A, Trifirò G; EU-ADR consortium.Fieschi M, Sturkenboom M, van der Lei J, Pariente A, Trifirò G; EU-ADR consortium. | ||||
1, LESIM, ISPED, University Bordeaux Segalen, Bordeaux,France 2,LERTIM, EA 3283, Faculté de Médecine, Université AixMarseille 2, Marseille, France 3,Department of Medical Informatics, Erasmus University Medical Center, Rotterdam,The Netherlands 4,Regional Health Agency of ARS, Florence, Italy 5,Health Search—Italian College of General Practitioners,Florence, Italy 6,Pedianet—Societa’ Servizi Telematici SRL, Padova, Italy 7,Centre on Public Health,University of Milano-Bicocca,Milano, Italy 8, PHARMO Coöperation UA,Utrecht, The Netherlands 9,Department of Primary Care and Public Health Sciences, Kings College, London,UK 10 Aarhus University Hospital,Århus Sygehus, Denmark 11 INSERM U 657, University Bordeaux Segalen, Bordeaux,France 12Department of Epidemiology,Erasmus University Medical Center, Rotterdam, The Netherlands 13, Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy | ||||
J Am Med Inform Assoc. 2013 Jan 1;20(1):184-92. doi: 10.1136/amiajnl-2012-000933. Epub 2012 Sep 6. |
||||
, Article | ||||
, Europe, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22955495 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Methodology | 2013 | English | , Retrospective database analysis | |
Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries | ||||
Coloma PM, Valhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M, Mosseveld M, Morabito P, Schuemie MJ, Van Der Lei J, Sturkenboom M, Trifiro G, EU-ADR Consortium. | ||||
Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, The Netherlands. | ||||
BMJ Open2013;3:e002862 doi:10.1136/bmjopen-2013-002862 |
||||
, Article | ||||
, Europe, Italy | ||||
Abstract: http://bmjopen.bmj.com/content/3/6/e002862.abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Methodology | 2013 | English | , Retrospective database analysis | |
Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm. | ||||
Halcox JP1, Tubach F2, Sazova O3, Sweet S4, Medina J5; EURIKA steering committee. | ||||
1Wales Heart Research Institute, Cardiff University School of Medicine, UK halcoxjp@cardiff.ac.uk. 2Assistance-Publique-Hôpitaux de Paris, France; Université Paris Diderot, France. 3AstraZeneca Global Medical Affairs, UK. 4Research Evaluation Unit, Oxford PharmaGenesis Ltd, UK. 5Observational Research Centre, AstraZeneca, Spain. | ||||
Eur J Prev Cardiol. 2015 Feb;22(2):200-2. doi: 10.1177/2047487313507680. Epub 2013 Oct |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24092875 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2013 | English | , Prospective study | |
Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. | ||||
Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RM, Pedersen L, Innocenti F, Mazzaglia G, Picelli G, Van Der Lai J, Sturkenboom MC. | ||||
Drug Saf. 2013 Oct;36 Suppl 1:S159-69. doi: 10.1007/s40264-013-0109-8. |
||||
, Article | ||||
, Europe, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24166232 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Methodology | 2013 | English | , Methodology, Retrospective database analysis | |
Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues? | ||||
Valkhoff VE1, Schade R, 't Jong GW, Romio S, Schuemie MJ, Arfe A, Garbe E, Herings R, Lucchi S, Picelli G, Schink T, Straatman H, Villa M, Kuipers EJ, Sturkenboom MC; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) project. | ||||
1Department of Medical Informatics, Erasmus University Medical Center, Dr, Molewaterplein, Rotterdam, The Netherlands | ||||
BMC Pediatr. 2013 Nov 19;13:192. doi: 10.1186/1471-2431-13-192. |
||||
, Article | ||||
, Europe, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24252465 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Miscellaneous, Pediatrics | 2013 | English | , Retrospective database analysis | |
A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. | ||||
Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, Fourrier-Reglat A, Molokhia M, Patadia V, Van Der Lei J, Sturkenboom M, Trifiro G. | ||||
Department of Medical Informatics, Erasmus Medical Center, Postbus 2040, 3000, CA, Rotterdam, The Netherlands. | ||||
Drug Saf. 2013 Jan;36(1):13-23. doi: 10.1007/s40264-012-0002-x |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23315292 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Methodology | 2013 | English | , Retrospective database analysis | |
Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe | ||||
Gao S, Barber B, Schabert V, Ferrufino C. | ||||
1,2Amgen, Thousand Oaks, CA, USA, 3IMS Health, Woodland Hills, CA, USA, 4IMS Health, Alexandria, VA, USA | ||||
Curr Med Res Opin |
||||
, Manuscript in preparation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2012 | English | , Retrospective database analysis | |
Guidelines for primary cardiovascular prevention are not being observed in clinical practice. EURIKA study shows European shortcomings. | ||||
Perk J1. | ||||
1Institutionen för hälso- och vårdvetenskap, Linnéuniversitetet, Kalmar | ||||
Lakartidningen. 2012 Jun 5-19;109(23-24):1164-6. |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22834209 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2012 | English | , Prospective study | |
Electronic healthcare databases for active drug safety surveillance: is there enough leverage. | ||||
Coloma PM1, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, van der Lei J, Sturkenboom M; EU-ADR Consortium. | ||||
1Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands | ||||
Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):611-21. doi: 10.1002/pds.3197. Epub 2012 Feb 8. |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22315152 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Miscellaneous | 2012 | English | , Retrospective database analysis | |
Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study. | ||||
Valkhoff VE1, van Soest EM, Masclee GM, de Bie S, Mazzaglia G, Molokhia M, Kuipers EJ, Sturkenboom MC. | ||||
1Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, the Netherlands | ||||
Aliment Pharmacol Ther. 2012 Oct;36(8):790-9. doi: 10.1111/apt.12028. Epub 2012 Aug 28. |
||||
, Article | ||||
, Europe, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22928490 | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2012 | English | , Retrospective database analysis | |
Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. | ||||
Trifirò G1, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R & Sturkenboom MC. | ||||
1Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands. g.trifiro@erasmusmc.nl | ||||
Drug Saf. 2012 Feb 1;35(2):159-71. doi: 10.2165/11594940-000000000-00000. |
||||
, Article | ||||
, Europe, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22204718 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug safety, Neurological disorders | 2012 | English | , Retrospective database analysis | |
Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. | ||||
Dallongeville J1, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JP, Massó-González EL, Perk J, Sazova O, Steg PG, Artalejo FR; EURIKA Investigators | ||||
1Service d'Epidemiologie et Santé Publique, Institut Pasteur de Lille, INSERM U744, Univ Lille Nord de France | ||||
Eur J Prev Cardiol. 2012 Jun;19(3):541-50. doi: 10.1177/1741826711407705. Epub 2011 Apr 18. |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21502280 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2012 | English | , Prospective study | |
Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. | ||||
Schuemie MJ1, Coloma PM, Straatman H, Herings RM, Trifirò G, Matthews JN, Prieto-Merino D, Molokhia M, Pedersen L, Gini R, Innocenti F, Mazzaglia G, Picelli G, Scotti L, van der Lei J, Sturkenboom MC. | ||||
1Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands | ||||
Med Care. 2012 Oct;50(10):890-7. |
||||
, Article | ||||
, Europe, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22929992 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Methodology | 2012 | English | , Retrospective database analysis | |
Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. | ||||
Correll CU, Cañas F, Larmo I, Levy P, Montes JM, Fagiolini A, Papageorgiou G, Rossi A, Sturlason R, Zink M. | ||||
Eur Psychiatry. 2011 Mar;26(1 Suppl 1):3-16. doi: 10.1016/S0924-9338(11)71709-6. |
||||
, Article | ||||
, Europe | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21440219 | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2011 | English | ||
European study of health related quality-of-life in patients with gout. | ||||
Van Vlaenderen I1, Strens D1, Annemans L, Murdock SC | ||||
1 IMS Health, Brussels, Belgium | ||||
Ann Rheum Dis., 2008, 67(Suppl II): 580 |
||||
, Article | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2008 | English | , Quality of life | |
Economic evaluations in pricing and reimbursement process of pharmaceutical products in Europe | ||||
Vieta A, Lara N, Badia X | ||||
XXVII Jornadas de EconomÃa de la Salud (AES). La Coruña 6-8 June |
||||
, Oral presentation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | Spanish | , Pricing & Reimbursement | |
European databases and retrospective database analysis | ||||
Elise Pelletier; Erik Spaepen | ||||
ISPOR 2007 10th Annual European Congress |
||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | , Review | |
Experienced HIV/AIDS patients in different European healthcare settings | ||||
Moeremans Karen, Annemans Lieven,; Smets Erik, Wyffels Veronique, Lothgren Mickael , Allegri Gabriele | ||||
ISPOR 2007 10th Annual European Congress |
||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2007 | English | ||
A European prospective real-life observational study of Quality of Life in patients with Acromegaly. | ||||
Webb S, Colao A, Caron Ph, Carvalheiro M, Erturk E, Pokrajac-Simeunovic A, Schopohl J, Tsagarakis S, Pearson I, Badia X, Caglio S, Vincenzi B. | ||||
8th European Congress of Endocrinology (ECE2006), Glasgow (UK) 1-5 April |
||||
, Oral presentation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Endocrinology | 2006 | English | ||
European organisation for research and treatment of cancer. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. | ||||
Repetto L, Moeremans K, Annemans L | ||||
Cancer Treat Rev., 2006, 32(Suppl 2): S5-9 |
||||
, Manuscript in preparation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2006 | English | , Quality of life | |
Costs of managing asthma as defined by a derived Asthma Control Test (ACT) score in seven European countries. | ||||
Vervloet D1, Williams AE2, Lloyd A3, Clark TJH4. | ||||
1 Hôpital Sainte-Marguerite, ‘UPRES 3287’, Université de la Méditerranée, Marseilles, France, 2 GlaxoSmithKline Research and Development, Greenford, 3 Fourth Hurdle Consulting, London, 4 National Heart and Lung Institute, Imperial College, London, UK. | ||||
European Respiratory Review 2006; 15:(98): 17–23 |
||||
, Manuscript in preparation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2006 | English | , Cost of illness | |